|
市場調査レポート
商品コード
1275636
体外診断の世界市場:提供別、技術別、用途別、診断アプローチ別 - 予測(~2030年)In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics, Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)-Global Forecast to 2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
体外診断の世界市場:提供別、技術別、用途別、診断アプローチ別 - 予測(~2030年) |
出版日: 2023年05月17日
発行: Meticulous Research
ページ情報: 英文 526 Pages
納期: 即納可能
|
世界の体外診断の市場規模は、2030年までに1,301億米ドルに達し、2023年~2030年にCAGRで4.6%の成長が予測されています。市場の成長は、主に高齢者人口の増加に伴う慢性疾患の有病率の上昇、急性と慢性の感染症の流行、研究活動資金の増加、疾患の早期診断に関する意識の高まり、ポイントオブケア(PoC)診断や迅速診断の需要の高まり、医療支出の増加、研究活動資金の増加などに起因しています。
当レポートでは、世界の体外診断市場について調査分析し、市場動向の考察、地域とセグメントの評価、競合情勢などを提供しています。
In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC)-Global Forecast to 2030
The global in vitro diagnostics market is expected to register a CAGR of 4.6% from 2023 to 2030 to reach $130.1 billion by 2030.
The growth of the global in vitro diagnostics market is mainly attributed to the rising prevalence of chronic diseases coupled with the increasing geriatric population, rising prevalence of acute and chronic infectious diseases, increasing funding for research activities, growing awareness regarding early disease diagnosis, growing demand for point-of-care (POC) diagnostics and rapid diagnosis, rising healthcare expenditure, and increasing funding for research activities. Moreover, the inclination of emerging economies toward personalized medicine and advancements in genomics & proteomics offer significant growth opportunities for the players operating in this market.
Based on offering, the reagents & kits segment is expected to grow with the fastest growth during the forecast period owing to its advantages as it can detect several markers simultaneously, which is useful for detecting complex diseases. Its technological superiority and the ability to facilitate chemical reactions further support the growth of this segment.
Based on the technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the market. The largest share of the segment attributed to its improved specificity, cost-savings and enhanced throughput when automated, minimizing the false positive test results by targeting specific molecules, as well as improved diagnosis of infections such as orthopedic infections.
Based on diagnostic approach, the laboratory testing segment is expected to account for the largest share of the market. Lab testing is a traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing. Factors such as low costs of tests, highly sensitive analyzers, more accuracy and reliability, and accessibility & availability of multiple IVD tests support the largest share of the segment.
Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the global in vitro diagnostics (IVD) market owing to the high prevalence of infectious diseases, government initiatives to promote awareness and testing, and emerging outbreaks of infectious diseases around the world.
Based on end user, the hospitals & clinics segment is expected to grow with the highest CAGR during the forecast period. Patient inflows at hospitals & clinics and subsequent increase in the volume of testing carried out in hospitals and clinics due to the outbreak of COVID-19 support the growth of this segment.
An in-depth analysis of the geographical scenario of the global in-vitro diagnostics (IVD) market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the IVD market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The high prevalence of chronic and infectious diseases, high awareness regarding early disease diagnosis, high adoption of advanced diagnostic products, and presence of funding coupled with novel developments in diagnostic technologies support the large share of this market.
The key players operating in the global in-vitro diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMerieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Wama Diagnostica (Brazil), Wiener Laboratorios SAIC (Argentina), QuidelOrtho Corporation (U.S.), Agilent Technologies Inc. (U.S.), and DiaSorin S.p.A. (Italy).
Global In Vitro Diagnostics Market Assessment-by Offering
Global In Vitro Diagnostics Market Assessment-by Technology
(Other Molecular Diagnostic Technologies majorly include electrophoresis, Ligase Chain Reaction (LCR), Northern Blot, and Southern Blot)
(Other IVD technologies comprise anatomical pathology, histochemistry, and loop-mediated amplification).
Global In Vitro Diagnostics Market Assessment-by Application
(Other applications comprise drugs of abuse tests, coagulation tests, neonatal testing, genetic testing, and neurological disorders testing).
(Other infectious diseases include congenital infections, meningitis, norovirus (stomach flu), hand, foot, and mouth disease (HFMD), and pertussis).
Global In Vitro Diagnostics Market Assessment-by Diagnostic Approach
Global In Vitro Diagnostics Market Assessment-by End User
(Other end users comprise nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories.)
Global In vitro Diagnostics Market Assessment-by Geography